These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11217916)

  • 1. A search for sources of drug resistance by the 4D-QSAR analysis of a set of antimalarial dihydrofolate reductase inhibitors.
    Santos-Filho OA; Hopfinger AJ
    J Comput Aided Mol Des; 2001 Jan; 15(1):1-12. PubMed ID: 11217916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free energy force field (FEFF) 3D-QSAR analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors.
    Santos-Filho OA; Mishra RK; Hopfinger AJ
    J Comput Aided Mol Des; 2001 Sep; 15(9):787-810. PubMed ID: 11776291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-dimensional quantitative structure-activity relationship analysis of a series of interphenylene 7-oxabicycloheptane oxazole thromboxane A2 receptor antagonists.
    Albuquerque MG; Hopfinger AJ; Barreiro EJ; de Alencastro RB
    J Chem Inf Comput Sci; 1998; 38(5):925-38. PubMed ID: 9770304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring QSAR, pharmacophore mapping and docking studies and virtual library generation for cycloguanil derivatives as PfDHFR-TS inhibitors.
    Ojha PK; Roy K
    Med Chem; 2011 May; 7(3):173-99. PubMed ID: 21486210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
    Fogel GB; Cheung M; Pittman E; Hecht D
    J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of dihydrofolate reductases from multiple strains of Plasmodium falciparum using mathematical descriptors of their inhibitors.
    Basak SC; Mills D; Hawkins DM
    Chem Biodivers; 2011 Mar; 8(3):440-53. PubMed ID: 21404427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Plasmodium falciparum dihydrofolate reductase-based in vitro screen for antifolate antimalarials.
    Brobey RK; Sano G; Itoh F; Aso K; Kimura M; Mitamura T; Horii T
    Mol Biochem Parasitol; 1996 Oct; 81(2):225-37. PubMed ID: 8898337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays.
    Bunyarataphan S; Leartsakulpanich U; Taweechai S; Tarnchompoo B; Kamchonwongpaisan S; Yuthavong Y
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3631-7. PubMed ID: 16954316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
    Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
    J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil.
    Basco LK; Ringwald P
    Am J Trop Med Hyg; 2000 Feb; 62(2):271-6. PubMed ID: 10813484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmodium falciparum: kinetic interactions of WR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase.
    Hekmat-Nejad M; Rathod PK
    Exp Parasitol; 1997 Nov; 87(3):222-8. PubMed ID: 9371087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the structural requirements in diverse scaffolds for the inhibition of P. falciparum dihydroorotate dehydrogenase (PfDHODH) using 2D-QSAR, 3D-pharmacophore and structure-based energy- optimized pharmacophore models.
    Aher RB; Roy K
    Comb Chem High Throughput Screen; 2015; 18(2):217-26. PubMed ID: 25543684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
    Yuthavong Y; Vilaivan T; Chareonsethakul N; Kamchonwongpaisan S; Sirawaraporn W; Quarrell R; Lowe G
    J Med Chem; 2000 Jul; 43(14):2738-44. PubMed ID: 10893311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme.
    Adane L; Bharatam PV
    J Mol Graph Model; 2009 Nov; 28(4):357-67. PubMed ID: 19796975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling and informatics in the analysis of P. falciparum DHFR enzyme inhibitors.
    Adane L; Bharatam PV
    Curr Med Chem; 2008; 15(16):1552-69. PubMed ID: 18673224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship and comparative docking studies for cycloguanil analogs as PfDHFR-TS inhibitors.
    Sivaprakasam P; Tosso PN; Doerksen RJ
    J Chem Inf Model; 2009 Jul; 49(7):1787-96. PubMed ID: 19588935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
    Sirichaiwat C; Intaraudom C; Kamchonwongpaisan S; Vanichtanankul J; Thebtaranonth Y; Yuthavong Y
    J Med Chem; 2004 Jan; 47(2):345-54. PubMed ID: 14711307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum.
    Wooden JM; Hartwell LH; Vasquez B; Sibley CH
    Mol Biochem Parasitol; 1997 Mar; 85(1):25-40. PubMed ID: 9108546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
    Tarnchompoo B; Sirichaiwat C; Phupong W; Intaraudom C; Sirawaraporn W; Kamchonwongpaisan S; Vanichtanankul J; Thebtaranonth Y; Yuthavong Y
    J Med Chem; 2002 Mar; 45(6):1244-52. PubMed ID: 11881993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro sensitivity of Plasmodium falciparum to anti-folinic agents (trimethoprim, pyrimethamine, cycloguanil): a study of 29 African strains].
    Basco LK; Le Bras J
    Bull Soc Pathol Exot; 1997; 90(2):90-3. PubMed ID: 9289260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.